Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 167

1.

A Novel Three-Dimensional Human Peritubular Microvascular System.

Ligresti G, Nagao RJ, Xue J, Choi YJ, Xu J, Ren S, Aburatani T, Anderson SK, MacDonald JW, Bammler TK, Schwartz SM, Muczynski KA, Duffield JS, Himmelfarb J, Zheng Y.

J Am Soc Nephrol. 2015 Dec 11. pii: ASN.2015070747. [Epub ahead of print]

PMID:
26657868
2.

Characterization of KIR intermediate promoters reveals four promoter types associated with distinct expression patterns of KIR subtypes.

Li H, Wright PW, McCullen M, Anderson SK.

Genes Immun. 2016 Jan;17(1):66-74. doi: 10.1038/gene.2015.56. Epub 2015 Dec 10.

PMID:
26656451
3.

Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance).

Brown PD, Anderson SK, Carrero XW, O'Neill BP, Giannini C, Galanis E, Shah SA, Abrams RA, Curran WJ Jr, Buckner JC, Shaw EG.

Neurooncol Pract. 2015 Dec;2(4):199-204. Epub 2015 Aug 6.

PMID:
26640699
4.

The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.

Huang RY, Rahman R, Ballman KV, Felten SJ, Anderson SK, Ellingson BM, Nayak L, Lee EQ, Abrey LE, Galanis E, Reardon DA, Pope WB, Cloughesy TF, Wen PY.

Clin Cancer Res. 2016 Feb 1;22(3):575-81. doi: 10.1158/1078-0432.CCR-14-3040. Epub 2015 Oct 21.

PMID:
26490307
5.

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, Fan JB, Geiger XJ, McCullough AE, Chen B, Jenkins RB, Sledge GW, Winer EP, Gralow JR, Reinholz MM.

J Clin Oncol. 2015 Mar 1;33(7):701-8. doi: 10.1200/JCO.2014.57.6298. Epub 2015 Jan 20.

6.

A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.

Ma DJ, Galanis E, Anderson SK, Schiff D, Kaufmann TJ, Peller PJ, Giannini C, Brown PD, Uhm JH, McGraw S, Jaeckle KA, Flynn PJ, Ligon KL, Buckner JC, Sarkaria JN.

Neuro Oncol. 2015 Sep;17(9):1261-9. doi: 10.1093/neuonc/nou328. Epub 2014 Dec 18.

PMID:
25526733
7.

Interleukin-1 and interferon-γ orchestrate β-glucan-activated human dendritic cell programming via IκB-ζ modulation.

Cardone M, Dzutsev AK, Li H, Riteau N, Gerosa F, Shenderov K, Winkler-Pickett R, Provezza L, Riboldi E, Leighty RM, Orr SJ, Steinhagen F, Wewers MD, Sher A, Anderson SK, Goldszmid R, McVicar DW, Lyakh L, Trinchieri G.

PLoS One. 2014 Dec 4;9(12):e114516. doi: 10.1371/journal.pone.0114516. eCollection 2014.

8.

CMS-required visits adversely impact Seattle area hemodialysis program.

Muczynski KA, Anderson SK.

Nephrol News Issues. 2014 Aug;28(9):32-4.

PMID:
25223075
9.

Exploring primary brain tumor patient and caregiver needs and preferences in brief educational and support opportunities.

Lageman SK, Brown PD, Anderson SK, Lachance DH, Yan E, Laack NN, Cerhan JH.

Support Care Cancer. 2015 Mar;23(3):851-9. doi: 10.1007/s00520-014-2413-y. Epub 2014 Sep 14.

PMID:
25218608
10.

Probabilistic bidirectional promoter switches: noncoding RNA takes control.

Anderson SK.

Mol Ther Nucleic Acids. 2014 Sep 2;3:e191. doi: 10.1038/mtna.2014.42.

11.

Characterization of a weakly expressed KIR2DL1 variant reveals a novel upstream promoter that controls KIR expression.

Wright PW, Li H, Huehn A, O'Connor GM, Cooley S, Miller JS, Anderson SK.

Genes Immun. 2014 Oct;15(7):440-8. doi: 10.1038/gene.2014.34. Epub 2014 Jul 3.

12.

Transcriptional regulation of Munc13-4 expression in cytotoxic lymphocytes is disrupted by an intronic mutation associated with a primary immunodeficiency.

Cichocki F, Schlums H, Li H, Stache V, Holmes T, Lenvik TR, Chiang SC, Miller JS, Meeths M, Anderson SK, Bryceson YT.

J Exp Med. 2014 Jun 2;211(6):1079-91. doi: 10.1084/jem.20131131. Epub 2014 May 19.

13.

Functional NK cell repertoires are maintained through IL-2Rα and Fas ligand.

Felices M, Lenvik TR, Ankarlo DE, Foley B, Curtsinger J, Luo X, Blazar BR, Anderson SK, Miller JS.

J Immunol. 2014 Apr 15;192(8):3889-97. doi: 10.4049/jimmunol.1302601. Epub 2014 Mar 14.

14.

Mutational and structural analysis of KIR3DL1 reveals a lineage-defining allotypic dimorphism that impacts both HLA and peptide sensitivity.

O'Connor GM, Vivian JP, Widjaja JM, Bridgeman JS, Gostick E, Lafont BA, Anderson SK, Price DA, Brooks AG, Rossjohn J, McVicar DW.

J Immunol. 2014 Mar 15;192(6):2875-84. doi: 10.4049/jimmunol.1303142. Epub 2014 Feb 21.

15.

Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.

Purrington KS, Slager S, Eccles D, Yannoukakos D, Fasching PA, Miron P, Carpenter J, Chang-Claude J, Martin NG, Montgomery GW, Kristensen V, Anton-Culver H, Goodfellow P, Tapper WJ, Rafiq S, Gerty SM, Durcan L, Konstantopoulou I, Fostira F, Vratimos A, Apostolou P, Konstanta I, Kotoula V, Lakis S, Dimopoulos MA, Skarlos D, Pectasides D, Fountzilas G, Beckmann MW, Hein A, Ruebner M, Ekici AB, Hartmann A, Schulz-Wendtland R, Renner SP, Janni W, Rack B, Scholz C, Neugebauer J, Andergassen U, Lux MP, Haeberle L, Clarke C, Pathmanathan N, Rudolph A, Flesch-Janys D, Nickels S, Olson JE, Ingle JN, Olswold C, Slettedahl S, Eckel-Passow JE, Anderson SK, Visscher DW, Cafourek VL, Sicotte H, Prodduturi N, Weiderpass E, Bernstein L, Ziogas A, Ivanovich J, Giles GG, Baglietto L, Southey M, Kosma VM, Fischer HP; GENICA Network, Reed MW, Cross SS, Deming-Halverson S, Shrubsole M, Cai Q, Shu XO, Daly M, Weaver J, Ross E, Klemp J, Sharma P, Torres D, Rüdiger T, Wölfing H, Ulmer HU, Försti A, Khoury T, Kumar S, Pilarski R, Shapiro CL, Greco D, Heikkilä P, Aittomäki K, Blomqvist C, Irwanto A, Liu J, Pankratz VS, Wang X, Severi G, Mannermaa A, Easton D, Hall P, Brauch H, Cox A, Zheng W, Godwin AK, Hamann U, Ambrosone C, Toland AE, Nevanlinna H, Vachon CM, Couch FJ.

Carcinogenesis. 2014 May;35(5):1012-9. doi: 10.1093/carcin/bgt404. Epub 2013 Dec 9.

16.

An integrated model of the transcriptome of HER2-positive breast cancer.

Kalari KR, Necela BM, Tang X, Thompson KJ, Lau M, Eckel-Passow JE, Kachergus JM, Anderson SK, Sun Z, Baheti S, Carr JM, Baker TR, Barman P, Radisky DC, Joseph RW, McLaughlin SA, Chai HS, Camille S, Rossell D, Asmann YW, Thompson EA, Perez EA.

PLoS One. 2013 Nov 1;8(11):e79298. doi: 10.1371/journal.pone.0079298. eCollection 2013.

17.

Differential expression of the Ly49G(B6), but not the Ly49G(BALB), receptor isoform during natural killer cell reconstitution after hematopoietic stem cell transplantation.

Barao I, Wright PW, Sungur CM, Anderson SK, Redelman D, Murphy WJ.

Biol Blood Marrow Transplant. 2013 Oct;19(10):1446-52. doi: 10.1016/j.bbmt.2013.07.021. Epub 2013 Jul 31.

18.

Identification of a KIR antisense lncRNA expressed by progenitor cells.

Wright PW, Huehn A, Cichocki F, Li H, Sharma N, Dang H, Lenvik TR, Woll P, Kaufman D, Miller JS, Anderson SK.

Genes Immun. 2013 Oct;14(7):427-33. doi: 10.1038/gene.2013.36. Epub 2013 Jul 18.

19.

Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.

Galanis E, Anderson SK, Lafky JM, Uhm JH, Giannini C, Kumar SK, Kimlinger TK, Northfelt DW, Flynn PJ, Jaeckle KA, Kaufmann TJ, Buckner JC.

Clin Cancer Res. 2013 Sep 1;19(17):4816-23. doi: 10.1158/1078-0432.CCR-13-0708. Epub 2013 Jul 5.

20.

Contrasting effects of anti-Ly49A due to MHC class I cis binding on NK cell-mediated allogeneic bone marrow cell resistance.

Alvarez M, Sungur CM, Ames E, Anderson SK, Pomeroy C, Murphy WJ.

J Immunol. 2013 Jul 15;191(2):688-98. doi: 10.4049/jimmunol.1300202. Epub 2013 Jun 10.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk